A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (RESONATE™)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01578707|
Recruitment Status : Completed
First Posted : April 17, 2012
Results First Posted : October 12, 2015
Last Update Posted : December 18, 2019
|Condition or disease||Intervention/treatment||Phase|
|Relapsed or Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma||Drug: ofatumumab Drug: ibrutinib||Phase 3|
Study PCYC-1112-CA is a randomized, multicenter, open-label, phase 3 study of the Bruton's Tyrosine Kinase (BTK) inhibitor Ibrutinib (PCI-32765) versus Ofatumumab in patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Patients randomized to the ofatumumab arm may be considered to receive next subsequent therapy with ibrutinib.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||391 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|
|Actual Study Start Date :||June 2012|
|Actual Primary Completion Date :||November 2013|
|Actual Study Completion Date :||October 25, 2018|
Active Comparator: Ofatumumab (Arm A)
An anti-CD20 monoclonal antibody
The ofatumumab (IV) dosage and schedule is 12 doses administered over 24 weeks or until disease progression, unacceptable toxicity.
Week 1: 300 mg initial dose Week 2 through 8: 2,000 mg (once weekly) Week 12, 16, 20 and 24: 2,000 mg (every 4 weeks)
Experimental: ibrutinib (Arm B)
A Bruton Tyrosine Kinase Inhibitor
ibrutinib 420 mg (3 x 140-mg capsules) will be administered orally once daily until disease progression or unacceptable toxicity
- PFS (Progression Free Survival) by Independent Review Committee (IRC), Limited to the Time of Primary Analysis 06 November 2013 [ Time Frame: Analysis was conducted after observing approximately 117 PFS events, which occurred about 18 months after the first subject was enrolled. ]The primary objective of this study was to evaluate the efficacy of ibrutinib compared to ofatumumab based on independent review committee (IRC) assessment of progression-free survival (PFS) according to 2008 IWCLL guidelines.
- Overall Response Rate (ORR) by Independent Review Committee (IRC) [ Time Frame: About 18 months after the first subject was enrolled ]Overall Response Rate per the IWCLL 2008 criteria as assessed by IRC, limited to the time of primary analysis 06 November 2013
- OS (Overall Survival) [ Time Frame: OS analysis was conducted at the time of study closure, including up to 6 years of study follow-up ]OS analysis was conducted at the time of study closure, with no adjustment for crossover from the ofatumumab arm to the ibrutinib arm
- Rate of Sustained Hemoglobin and Platelet Improvement [ Time Frame: From study initiation to study closure, including up to 6 years of study follow-up ]Proportion of subjects with hemoglobin (HgB) increase >=20 g/L and platelet (PLT) increase >=50% over baseline continuously for >=56 days without blood transfusions or growth factors.
- Progression Free Survival (PFS) by Investigator With up to 6 Years of Study Follow-up [ Time Frame: From study initiation to study closure, including up to 6 years of study follow-up ]Long-Term Progression Free Survival as assessed by the investigator with up to 6 years of study follow-up
- Overall Response Rate (ORR) by Investigator [ Time Frame: From study initiation to study closure, including up to 6 years of study follow-up ]Overall response per the IWCLL 2008 criteria as assessed by Investigator with up to 6 years of study follow-up
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01578707
|Study Director:||Anita Szoke, MD||Pharmacyclics LLC.|